Try our beta test site

Staccato Loxapine PK in Smokers and Nonsmokers

This study has been completed.
Information provided by:
Alexza Pharmaceuticals, Inc. Identifier:
First received: April 1, 2009
Last updated: June 18, 2009
Last verified: June 2009
The objective of this trial is to assess the pharmacokinetics of a single dose of 10 mg Staccato Loxapine administered to smokers compared to nonsmokers.

Condition Intervention Phase
Smoking, Cigarette
Drug: Staccato Loxapine
Phase 1

Alexza Pharmaceuticals, Inc. has indicated that access to an investigational treatment associated with this study is available outside the clinical trial.  

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Pharmacokinetics of Staccato® Loxapine for Inhalation in Smokers Compared to Nonsmokers

Resource links provided by NLM:

Further study details as provided by Alexza Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • Noncompartmental Pharmacokinetic parameters [ Time Frame: 24 hours ]

Secondary Outcome Measures:
  • Vital signs [ Time Frame: 24 hours ]
  • Treatment emergent adverse events [ Time Frame: 24 hours ]
  • Sedation visual analog scale [ Time Frame: 24 hours ]

Enrollment: 35
Study Start Date: April 2009
Study Completion Date: June 2009
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Healthy smokers
Drug: Staccato Loxapine
Active Comparator: 2
Healthy nonsmokers
Drug: Staccato Loxapine


Ages Eligible for Study:   20 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Normal spirometry at screening and in good general health as determined by a complete medical history, physical examination, 12-lead ECG, blood chemistry profile, hematology, and urinalysis,
  • Smokers must have a history of smoking > 15 cigarettes/day currently and for at least the last 2 years,
  • Nonsmokers must have never smoked > 5 cigarettes/day and not smoking at all for at least the last 2 years.

Exclusion Criteria:

  • Any acute illness in the 5 days,
  • Use of a bronchodilator for the treatment of wheezing within 12 months, OR
  • Any other disease or condition, by history, physical examination, or laboratory abnormalities that would present undue risk to the subject, or may confound the interpretation of study results.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00873769

United States, Indiana
Covance Clinical Research Unit, Inc.
Evansville, Indiana, United States, 47710
Sponsors and Collaborators
Alexza Pharmaceuticals, Inc.
Principal Investigator: Randall R. Stoltz, MD Covance Clincial Research Unit, Inc.
  More Information

Responsible Party: Robert S. Fishman, MD, Alexza Pharmaceuticals, Inc. Identifier: NCT00873769     History of Changes
Other Study ID Numbers: AMDC-004-106  27 February 2009 
Study First Received: April 1, 2009
Last Updated: June 18, 2009

Keywords provided by Alexza Pharmaceuticals, Inc.:
Staccato Loxapine

Additional relevant MeSH terms:
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on February 20, 2017